Skip to main content
All Posts By

Andy

GEN Names BioHealth Capital Region a Top 3 U.S. Biopharma Cluster for Fourth Year in a Row

By News

The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., has once again been named one of the nation’s Top 3 biopharma clusters by Genetic Engineering & Biotechnology News (GEN), marking the region’s fourth consecutive year in the Top 3.

GEN’s 2026 “Top 10 U.S. Biopharma Clusters” ranking was authored by Alex Philippidis, Senior Business Editor at GEN, who has long tracked the growth, competition, and evolution of life sciences ecosystems across the country. Philippidis will return to the BioHealth Capital Region Forum this year to discuss GEN’s updated Top 10 list, the movement within the national rankings, and what the latest findings suggest about the future of U.S. biopharma innovation.

In the 2026 ranking, GEN places the BioHealth Capital Region at No. 3 nationally, behind only Boston/Cambridge and the San Francisco Bay Area. The full article is available here: https://www.genengnews.com/topics/drug-discovery/top-10-u-s-biopharma-clusters-2026/

The recognition reinforces the region’s standing among the country’s strongest life sciences ecosystems and reflects the depth of its research institutions, federal assets, industry base, talent, lab infrastructure, and commercialization capacity.

Recognition carries special meaning for a region that set a public goal years ago to become a Top 3 biopharma cluster. Reaching that milestone was significant. Maintaining it for four consecutive years shows that the BioHealth Capital Region has moved beyond aspiration and into sustained national leadership.

GEN’s annual ranking evaluates U.S. biopharma clusters using five core indicators: NIH funding, venture capital funding, patents, lab space, and jobs. In the 2025 ranking, the BioHealth Capital Region ranked first nationally in biotechnology-related patents and third in both NIH funding and lab space, helping secure its Top 3 position despite broader economic and industry headwinds.

For the BioHealth Capital Region, this continued recognition by GEN is a proof point for the power of regional collaboration. Maryland, Virginia, and Washington, D.C. each bring distinct strengths to the ecosystem, but the region’s national competitiveness is strongest when those assets are connected. The presence of NIH, FDA, NIST, USP, major research universities, leading health systems, established biopharma companies, emerging startups, investors, and commercialization partners gives the region a differentiated role in advancing biohealth innovation.

“Being ranked Top 3 by GEN for the fourth year in a row is a moment to celebrate across the entire BioHealth Capital Region.” Said Rich Bendis, Founder, President and CEO of BioHealth Innovation, Inc. “Congratulations to the many partners across Maryland, Virginia, and Washington, D.C. who have helped make this possible, including our companies, universities, federal institutions, economic development organizations, investors, entrepreneurs, and ecosystem leaders. This recognition reflects years of collaboration and a shared commitment to growing one of the nation’s leading biohealth clusters.”

The 2026 GEN ranking also comes at an important moment for the industry. Cluster development is being shaped by national trends, including renewed capital activity, increased merger and acquisition activity, a revived IPO market, and continued investment in U.S.-based biomanufacturing. Those trends are highly relevant to the BioHealth Capital Region, where research strength, proximity to federal labs, manufacturing growth, and translational support continue to define the ecosystem’s value.

GEN’s 2026 Top 10 also showed movement among several other regions compared with 2025. The Top 3 remained unchanged, with Boston/Cambridge, the San Francisco Bay Area, and the BioHealth Capital Region holding their positions. Greater Philadelphia moved from No. 7 in 2025 to No. 5 in 2026, while North Carolina moved from No. 8 to No. 7. Chicagoland moved from No. 10 to No. 9. San Diego shifted from No. 5 to No. 6, Los Angeles/Orange County moved from No. 6 to No. 8, and Seattle moved from No. 9 to No. 10.

The full GEN 2026 Top 10 includes:

  1. Boston/Cambridge, MA
  2. San Francisco Bay Area
  3. BioHealth Capital Region, Maryland, Virginia, and Washington, D.C.
  4. New York/New Jersey
  5. Greater Philadelphia
  6. San Diego
  7. North Carolina
  8. Los Angeles/Orange County, CA
  9. Chicagoland
  10. Seattle

For the BioHealth Capital Region, the fourth consecutive Top 3 ranking in GEN is both a recognition and a call to action. It confirms that the region has the assets, talent, and infrastructure to compete with the largest life sciences hubs in the country. It also underscores the need to keep building: more company formation, more access to capital, more lab and manufacturing capacity, more workforce development, and more collaboration.

BioHealth Innovation Welcomes Caroline Popper and Julie Wilkinson as Entrepreneurs-in-Residence

By News

BioHealth Innovation, Inc. (BHI) is pleased to announce the addition of Caroline Popper and Julie Wilkinson as Entrepreneurs-in-Residence (EIRs). Together, they bring decades of experience across medical technology, diagnostics, digital health, commercialization strategy, FDA pathways, manufacturing, corporate development, and venture-building.

Popper is a business leader, physician, and lawyer with more than 30 years of experience in medical technology, diagnostics, and the life sciences. Her work has focused on technologies and services that improve healthcare efficiency, with a growing emphasis on the intersection of healthcare, biology, technology, and artificial intelligence.

She has held operational and strategic roles at BD and bioMérieux, served as Chief Business Officer of MDS Proteomics, founded Popper and Company, and co-founded The Sherpanis with Julie Wilkinson. She also served as Chief Commercial Officer of Johns Hopkins Precision Medicine and led commercialization activities for the Johns Hopkins Applied Physics Lab Healthcare Mission Area. She currently serves as co-chair of the American Bar Association Healthcare Section AI Task Force.

Wilkinson is a scientist, C-level executive, and entrepreneur with more than 30 years of experience advancing MedTech innovations through FDA clearance and GMP manufacturing across medical devices, digital health, and in vitro diagnostics. She has led R&D efforts at major health technology companies, including Abbott, Beckman Coulter, and Agilent, and founded and grew a life science service company from zero to $10 million before a successful exit.

Her expertise spans FDA product development pathways, MedTech technology readiness, investor diligence, product-market fit, value proposition development, business model design, and commercialization strategy. She was also part of the $2 billion RADx Tech NIBIB initiative, which helped create U.S. manufacturing capacity for COVID-19 tests, and has led company teams through FDA authorization and manufacturing scale-up for new diagnostics.

“Caroline and Julie bring the kind of hands-on operating experience that is invaluable to entrepreneurs and early-stage companies,” said BHI President and CEO, Rich Bendis. “Their combined expertise in diagnostics, MedTech, FDA strategy, commercialization, manufacturing, AI, and venture-building will strengthen BHI’s ability to support innovators as they move from promising technologies to market-ready solutions.”

“Caroline and I are very excited to join the BHI Entrepreneur-in-Residence team and support our capital region entrepreneurs as they accelerate the transformation of innovative ideas into market-ready products. Turning an idea into a successful commercial product takes far more than funding and determination, it requires the collaboration of experienced experts working together as an active team. The Entrepreneur-in-Residence program led by Rich Bendis exemplifies that collaborative approach and provides entrepreneurs with the strategic support needed to move innovation forward,” said Julie Wilkinson, New Entrepreneur-in-Residence, BioHealth Innovation.

As Entrepreneurs-in-Residence, Popper and Wilkinson will work with BHI and its partners to help emerging companies evaluate technology readiness, refine commercialization strategies, navigate regulatory and development milestones, assess market opportunities, and build stronger pathways toward investment, partnership, and growth.

Their addition reflects BHI’s continued commitment to expanding its EIR network with leaders who have deep technical expertise, operating experience, and a strong understanding of what it takes to move biohealth innovations from concept to commercialization.

Organizations and Institutions interested in EIR support through BHI are encouraged to contact Rich Bendis, President and CEO of BioHealth Innovation, at rbendis@biohealthinnovation.org.

About BioHealth Innovation, Inc.

BioHealth Innovation, Inc. (BHI) is a nonprofit innovation intermediary that accelerates the commercialization of promising biohealth technologies. BHI works with entrepreneurs, startups, research institutions, federal laboratories, universities, investors, and industry partners to help move science from discovery to market.

Through its Entrepreneurs-in-Residence program, non-dilutive funding support, international soft-landing services, and commercialization expertise, BHI helps companies and innovators strengthen business strategies, pursue funding, connect with partners, and navigate the path toward growth. BHI is also a founding member and manager of the BioHealth Capital Region brand, supporting the continued development of Maryland, Washington, D.C., and Virginia as one of the nation’s leading life sciences clusters.

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.